Journal of Advanced Research ( IF 11.4 ) Pub Date : 2021-08-11 , DOI: 10.1016/j.jare.2021.08.004 Xin Li 1, 2, 3 , Lingdan Kong 4 , Wei Hu 5 , Changchang Zhang 5 , Andrij Pich 2, 3, 6 , Xiangyang Shi 5, 7 , Xipeng Wang 1 , Lingxi Xing 1
|
Introduction
The striking imbalance between the ever-increasing amount of nanomedicines and low clinical translation of products has become the focus of intense debate. For clinical translation, the critical issue is to select the appropriate agents and combination regimen for targeted diseases, not to prepare increasingly complex nanoplatforms.
Objectives
A safe and efficient platform, α-tocopheryl succinate (α-TOS) married 2D molybdenum disulfide, was devised by a facile method and applied for cooperative imaging-guided photothermal-selective chemotherapy of ovarian carcinoma.
Methods
A novel platform of PEGylated α-TOS and folic acid (FA) conjugated 2D MoS2 nanoflakes was fabricated for the cooperative multimode computed tomography (CT)/photoacoustic (PA)/thermal imaging-guided photothermal-selective chemotherapy of ovarian carcinoma.
Results
The photothermal efficiency (65.3%) of the platform under safe near-infrared irradiation is much higher than that of other photothermal materials reported elsewhere. Moreover, the covalently linked α-TOS renders platform with selective chemotherapy for cancer cells. Remarkably, with these excellent properties, the platform can be used to completely eliminate the solid tumor by safe photothermal therapy, and then kill the residual cancer cells by selective chemotherapy to prevent tumor recurrence. More significantly, barely side effects occur in the whole treatment process. The excellent efficacy and safety benefits in vivo lead to the prominent survival rate of 100% over 91 days.
Conclusion
The safe and efficient platform might be a candidate of clinical nanomedicines for multimode theranostics. This study demonstrates an innovative thought in precise nanomedicine regarding the design of next generation of cancer theranostic protocol for potential clinical practice.
中文翻译：
用于协同成像引导光热选择性化疗的安全高效二维二硫化钼平台：临床前研究
介绍
不断增加的纳米药物数量与产品临床转化率低之间的显着不平衡已成为激烈争论的焦点。对于临床转化，关键问题是为靶向疾病选择合适的药物和组合方案，而不是制备越来越复杂的纳米平台。
目标
通过简便的方法设计了一种安全高效的α-生育酚琥珀酸酯（α-TOS）与二维二硫化钼结合的平台，并应用于协同成像引导的卵巢癌光热选择性化疗。
方法
为卵巢癌的协同多模计算机断层扫描（CT）/光声（PA）/热成像引导的光热选择性化学疗法制造了聚乙二醇化α-TOS和叶酸（FA）共轭2D MoS 2纳米片的新平台。
结果
该平台在安全近红外照射下的光热效率（65.3%）远高于其他地方报道的其他光热材料。此外，共价连接的α-TOS为癌细胞提供了选择性化疗的平台。值得注意的是，凭借这些优异的特性，该平台可以通过安全的光热疗法彻底消除实体瘤，然后通过选择性化疗杀死残留的癌细胞，防止肿瘤复发。更重要的是，整个治疗过程几乎没有副作用。体内优异的疗效和安全性优势导致 91 天以上的显着存活率 100%。
结论
安全高效的平台可能是多模式治疗学临床纳米药物的候选者。这项研究展示了精确纳米医学关于为潜在临床实践设计下一代癌症治疗方案的创新思想。
京公网安备 11010802027423号